Neuropathic Pain Market

Neuropathic Pain Market Outlook (2024 to 2034)

The neuropathic pain market size was around US$ 6,316.6 million in 2019. In 2024, the net worth of neuropathic drugs to be sold along with the nerve pain relief services is estimated to be around US$ 8,382.9 million. The global demand for neuropathic pain relief medications and services is poised to witness a CAGR of 5.7% through 2034. The industry is forecasted to reach a value of US$ 14,538.7 million by 2034.

The market is being propelled by the development of new mechanisms for nerve pain relief in neurological pain treatment. Neuropathic medications use these advancements to create novel, more effective medications that can fill the gaps in patient treatment procedures.

Neuropathic Pain Market Trends and Analysis

Localized pain treatment without systemic side effects has been made possible by advancements in topical neuropathy for pain relief. So, to produce topical remedies, market participants are investing in research and development, which has also broadened the spectrum of therapy alternatives.

Research on genomics and biomarkers in pain genetics has improved the knowledge and understanding of the processes behind neuropathic pain. By using this information, many pharmaceutical companies are also entering the sector to provide individualized and efficient pain management with novel medications.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 8,382.9 million
Forecasted Market Value (2034F)	US$ 14,538.7 million
Global Market Growth Rate (2024 to 2034)	5.7% CAGR
Anticonvulsant Segment Growth Rate (2024 to 2034)	6.4% CAGR
Chemotherapy-Induced Peripheral Neuropathy Segment Growth Rate (2024 to 2034)	6% CAGR
Retail Pharmacies Segment Growth Rate (2024 to 2034)	5.6% CAGR
North America Market Share (2024)	39.3%
Western Europe Market Share (2024)	28.2%
East Asia Market Share (2024)	14.2%
Key Companies Profiled	Pfizer Inc. Johnson & Johnson Services, Inc Bristol-Myers Squibb Company Sanofi S.A GlaxoSmithKline plc Eli Lilly and Company Teva Pharmaceutical Industries Ltd Baxter International Inc.

What is the Major Factor Fueling Growth in the Neuropathic Pain Market?

“Personalized and Virtual Neuropathic Nerve Damage Treatment”

The use of personalized medicine techniques that allow painkillers to be customized to the unique needs of each patient is an emerging trend in the neuropathic pain management market. So, leading market players have started providing tailored treatments based on lifestyle, genetic, and environmental variables, consequently improving treatment results and patient satisfaction.

By incorporating digital health technologies into pain treatment, neuropathic patient monitoring and engagement services have improved manifold in the last few years. During the pandemic years, neuropathic pain management service providers introduced wearable technology, telemedicine, and smartphone apps to help patients better measure and manage their pain at home.

Country-wise Insights

Country	CAGR (2024 to 2034)
United States	13.6%
Germany	6.2%
China	7.5%

What is Stimulating the United States Neuropathic Pain Market?

“Widespread Presence of Neuropathic Pain Support Groups in the United States”

The neuropathic pain industry in North America is valued at US$ 3,295 million in 2024. Different combination treatments are quite popular among patients in North America, and they also enable doctors to create drugs that target several pain circuits at once.

The neuropathic pain industries in the United States are expected to contribute to 78.1% of the North American market sales in 2024, making it the dominant country in the region. A sizable market for chronic pain relief drugs in the United States has been created by the growing percentage of the elderly population, who are more susceptible to neuropathic pain problems.

The growth of neuropathic pain solutions and products is likely to witness a CAGR of 13.6% through 2034. The healthcare sector’s emphasis on solving the complexities arising from the link between neuropathic pain and mental health is figured out to be the prime reason for market growth over the projected years. On the other hand, Canada is expected to witness a CAGR of 5.4% during this period.

Which is the Leading Market for Neuropathic Pain Relief Products in East Asia?

“China to Overtake Japan in Production of Neuropathic Pain Drugs”

The neuropathic pain market in East Asia is estimated to be worth around US$ 1,187 million in 2024. The market has grown in East Asian countries with the rising incidence of chronic nerve pain disorders such as diabetic neuropathy and post-herpetic neuralgia. Drug manufacturers in China, Japan, and South Korea are capitalizing on this expanding patient base by providing a range of medications for managing the symptoms of neuropathic pain.

The demand for neuropathic pain management medications and services in East Asia is likely to increase at 6.6% CAGR till 2034. The analysis also reveals that Japan, with a regional market share of 40.7% in 2024, is likely to be the leading market in East Asia. With a considerable share of the aged population, the demand for neuropathic pain diagnosis and management services in Japan is estimated to generate a revenue of around US$ 483 million in 2024.

On the other hand, the production and sales of neuropathic pain relief options in China are anticipated to grow at a faster rate than in Japan through the projected years. The China market is likely to expand at a CAGR of 7.5%, reaching a valuation of US$ 973 million by 2034.

Category-wise Insights

Which Type of Drug is Widely Used for Neuropathic Pain Recovery?

“Wide Use of Anticonvulsant Neuropathic Pain Relief Medication to Continue”

Attribute	Details
Market Share in 2024	42.6%

Among the different types or classes of drugs used for neuropathic pain relief, anticonvulsants constitute the leading drug segment, with an overall market share of 42.6% in 2024. Non-opioid alternatives for neuropathic pain management are receiving more attention due to rising concerns about opioid abuse. So, in line with this trend toward safer and longer-lasting pain management solutions, market players are supplying novel anticonvulsant painkillers. Through the projected years, the global demand for anticonvulsants is projected to rise at a CAGR of 6.4%, and the net worth of this segment is expected to reach US$ 6,666.4 million by 2034.

Tricyclic anti-depressant pharmaceuticals with age-appropriate dosages and formulations according to the specific needs of patients in different age groups constitute the second leading segment. The segment is poised to offer more opportunities for new market players by expanding at a CAGR of 5.8% from 2024 to 2034. The net revenue generated by this segment is expected to be around US$ 5,140.8 million by 2034, growing from US$ 2,928.6 million in 2024.

Which is the Leading Indication Segment in the Neuropathic Pain Market?

“Higher Demand Diabetic Neuropathy Treatment Solutions”

Attribute	Details
Market Share in 2024	45.8%

Based on the indication, the diabetic neuropathy segment is expected to contribute 45.8% of the total market share in 2024. The segment is poised to follow a growth rate of 5.6% over the next ten years. The segment is expected to create a business opportunity of US$ 6,439.7 million by 2034, increasing from US$ 3,837 million in 2024.

The development and implementation of chemotherapy-induced peripheral neuropathy solutions have strengthened through collaborations with pain experts and multidisciplinary care teams. Neuropathic pain drug suppliers who work closely with such medical experts to guarantee complete and patient-focused pain treatment plans are expected to gain higher profits from this segment. This segment is anticipated to witness a CAGR of 6% over the forecast period and reach a valuation of 6,630.6 million by 2034.

Competitive Landscape

Key players in the neuropathic pain market include Pfizer Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Sanofi S.A, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., and Baxter International Inc.

The legitimacy and accessibility of neuropathic pain drugs developed and improved through partnerships of leading players with healthcare organizations. Besides their strict adherence to health regulations, they are rewarded with a greater market share. However, programs run by the government that deal with managing chronic pain have supported the emergence of many neuropathic pain remedy suppliers recently.

Recent Developments

• In September 2022, a phase 2 clinical trial was started by AlgoTx Corporation to assess ATX01 for people who have chemotherapy-induced peripheral neuropathy (CIPN). For this innovative medication, topical amitriptyline, the company carried out the clinical trial in more than 40 locations across Europe and the United States.
• In January 2020, scientists at Huazhong Agricultural University in China established that neuropathic pain can be prevented by Synaptotagmin 1 (Syt-1), which is a synaptic vesicle protein. Researchers claim that it controls the exocytosis of neurotransmitters and neuropathic pain is alleviated by electroacupuncture by suppressing spinal Syt-1. Numerous other studies have also revealed that neuropathic pain can be effectively managed by using electroacupuncture methods.

Key Segments Covered by Neuropathic Pain Industry Survey Report

• By Drug Class :

  • Tricyclic Anti-Depressants
  • Anticonvulsants
  • SNRI's
  • Capsaicin Cream
  • Local Anesthesia
  • Opioids
  • Steroids
  • Other Drugs

• By Indication Type :

  • Diabetic Neuropathy
  • Trigeminal Neuralgia
  • Post-Herpetic Neuralgia
  • Chemotherapy-Induced Peripheral Neuropathy
  • Other Indications

• By Sales/Distribution Channel :

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Other Sales Channels

• By Region :

  • North America Market
  • Europe Market
  • Latin America Market
  • East Asia Market
  • South Asia & Oceania Market
  • Middle East & Africa (MEA) Market